Compare FATE & MGYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FATE | MGYR |
|---|---|---|
| Founded | 2007 | 1922 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 115.2M |
| IPO Year | 2013 | 2021 |
| Metric | FATE | MGYR |
|---|---|---|
| Price | $1.19 | $17.99 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 9.3K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.30% |
| EPS Growth | ★ 29.88 | 26.83 |
| EPS | N/A | ★ 0.50 |
| Revenue | ★ $6,646,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $34.84 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $13.62 |
| 52 Week High | $1.94 | $20.00 |
| Indicator | FATE | MGYR |
|---|---|---|
| Relative Strength Index (RSI) | 47.67 | 55.59 |
| Support Level | $1.06 | $16.42 |
| Resistance Level | $1.30 | $17.99 |
| Average True Range (ATR) | 0.08 | 0.44 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 53.70 | 92.09 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.